Johnson & Johnson (BVMF:JNJB34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 2.96T +41.6% |
| Revenue (ttm) | 505.03B +7.9% |
| Net Income | 110.27B -3.5% |
| EPS | 45.26 -3.9% |
| Shares Out | n/a |
| PE Ratio | 26.83 |
| Forward PE | 19.86 |
| Dividend | 1.17 (1.43%) |
| Ex-Dividend Date | May 26, 2026 |
| Volume | 3,935 |
| Open | 79.71 |
| Previous Close | 79.71 |
| Day's Range | 79.32 - 82.17 |
| 52-Week Range | 54.69 - 87.77 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 15, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong growth continues with double-digit gains across key products and new launches in immunology and oncology. TREMFYA and ICOTYDE drive immunology momentum, while RYBREVANT, ERLEADA, and INLEXZO expand oncology opportunities. Neuroscience and cardiovascular assets show robust progress.
Johnson & Johnson to Buy Firefly Bio for $1 Billion
Johnson & Johnson has agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that bolsters the drugmaker's oncology pipeline.
M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline
Johnson & Johnson stock was a hot topic on Monday after the company announced a $1 billion deal.
Johnson & Johnson to acquire Firefly Bio for $1B in cash
Johnson & Johnson entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink degrader antibody conjugate platform, for $1B in cash. Th...
Johnson & Johnson to buy Firefly Bio for $1 billion
Johnson & Johnson said on Monday it will acquire biotech Firefly Bio for $1 billion in cash, as it looks to expand its cancer drug pipeline.
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its propr...
J&J beats lawsuit alleging that talc caused three women's cancer
A Los Angeles jury on Friday sided with Johnson & Johnson in a lawsuit by the families of three women who alleged that the company's talc products caused ovarian cancer, finding that J&J was not neg...
Johnson & Johnson presents exploratory analyses from DAHLIAS study
Johnson & Johnson announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe Sjogren’s disease showing that participants with ...
Johnson & Johnson announces nipocalimab met primary endpoint in JASMINE study
Johnson & Johnson announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 and continued to demonstrate sustained reduction in…
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies a...
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preservin...
Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification
CNBC's Jim Cramer said investors should consider adding exposure to out-of-favor sectors if investors begin rotating away from high-flying technology stocks. He highlighted JPMorgan, Johnson & Johnson...
Johnson & Johnson announces Phase 3 Proteus study met primary endpoints
Johnson & Johnson announced results from the final analysis of the Phase 3 Proteus study showing the investigational use of apalutamide plus hormone therapy, given for six months before and…
Johnson & Johnson announces results from Phase 1b/2 OrigAMI-4 study
Johnson & Johnson announced results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck...
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris...
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publica...
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the ...
J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study
Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk o...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent responses observed across atypica...
Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study
Johnson & Johnson announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progression-free survival and overall survival ...
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
Building on the recent approval of Johnson & Johnson's TECVAYLI ® plus DARZALEX FASPRO® , MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI ® as early as second lin...
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
TREMFYA ® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis HORSHAM, Pa., May 28, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today th...
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
Partnership strategy has produced great pharma bargains—and left the company exposed.
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaq...